Select Publications
Journal articles
2024, 'Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling', BMC Genomics, 25, http://dx.doi.org/10.1186/s12864-024-10027-5
,2024, 'The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer', Genome Biology, 25, http://dx.doi.org/10.1186/s13059-023-03161-y
,2024, 'Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial', The Lancet Oncology, 25, pp. 317 - 325, http://dx.doi.org/10.1016/S1470-2045(24)00004-4
,2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7
,2024, 'Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.', Clin Cancer Res, http://dx.doi.org/10.1158/1078-0432.CCR-23-2975
,2024, 'Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer', Clinical Cancer Research, 30, pp. 754 - 766, http://dx.doi.org/10.1158/1078-0432.CCR-23-1796
,2024, 'Interleukin-3 production by basal-like breast cancer cells is associated with poor prognosis', Growth Factors, http://dx.doi.org/10.1080/08977194.2023.2297693
,2024, 'Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer', ESMO Open, http://dx.doi.org/10.1016/j.esmoop.2024.102974
,2024, 'Tumor Biomechanics Alters Metastatic Dissemination of Triple Negative Breast Cancer via Rewiring Fatty Acid Metabolism', Advanced Science, http://dx.doi.org/10.1002/advs.202307963
,2023, 'Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel', Drug Safety, 46, pp. 927 - 949, http://dx.doi.org/10.1007/s40264-023-01328-x
,2023, 'Oral vinorelbine to treat women with ectopic pregnancy: a phase 1 clinical safety and tolerability study', Fertility and Sterility, 120, pp. 695 - 696, http://dx.doi.org/10.1016/j.fertnstert.2023.05.161
,2023, 'Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy', Pharmaceutics, 15, http://dx.doi.org/10.3390/pharmaceutics15082017
,2023, 'Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).', Journal of Clinical Oncology, 41, pp. 1069 - 1069, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1069
,2023, 'Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor', Cancer Communications, 43, pp. 720 - 725, http://dx.doi.org/10.1002/cac2.12425
,2023, 'Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial', The Lancet, 401, pp. 1773 - 1785, http://dx.doi.org/10.1016/S0140-6736(23)00725-0
,2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063
,2023, 'Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-gs2-01
,2023, 'Abstract OT1-02-02: A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot1-02-02
,2023, 'Abstract OT2-01-10: WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-01-10
,2023, 'Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-ot2-10-05
,2023, 'Abstract PD13-04: PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy for previously treated, estrogen receptor+, HER2– advanced breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd13-04
,2023, 'Abstract PD13-12: PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd13-12
,2023, 'Abstract PD9-01: Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer', Cancer Research, 83, http://dx.doi.org/10.1158/1538-7445.sabcs22-pd9-01
,2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1148792
,2023, '383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study', Annals of Oncology, 34, pp. S338 - S339, http://dx.doi.org/10.1016/j.annonc.2023.09.560
,2023, '413P Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) who had rapid progression (RP) in acelERA BC', Annals of Oncology, 34, pp. S356 - S357, http://dx.doi.org/10.1016/j.annonc.2023.09.590
,2022, 'Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer', Clinical Breast Cancer, 22, pp. 792 - 800, http://dx.doi.org/10.1016/j.clbc.2022.08.011
,2022, 'Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis', Nature Communications, 13, http://dx.doi.org/10.1038/s41467-022-32255-7
,2022, 'An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer', Breast Cancer Research and Treatment, 195, pp. 275 - 287, http://dx.doi.org/10.1007/s10549-022-06690-5
,2022, 'Diagnostic value of 68Ga-DOTATATE PET-CT imaging for staging of ER+/PR+ HER2- breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18F-FDG PET-CT in a prospective pilot trial', Journal of Medical Imaging and Radiation Oncology, 66, pp. 731 - 737, http://dx.doi.org/10.1111/1754-9485.13342
,2022, '64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial', Pharmaceuticals, 15, http://dx.doi.org/10.3390/ph15070772
,2022, 'Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14102404
,2022, 'Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones', Cancers, 14, http://dx.doi.org/10.3390/cancers14092292
,2022, 'A new sophistication for breast cancer PDXs', Nature Cancer, 3, pp. 138 - 140, http://dx.doi.org/10.1038/s43018-021-00328-z
,2022, 'Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review', Cancers, 14, http://dx.doi.org/10.3390/cancers14040920
,2022, 'Epigenetic Therapies and Biomarkers in Breast Cancer', Cancers, 14, http://dx.doi.org/10.3390/cancers14030474
,2022, 'Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing', Breast Cancer Research and Treatment, 191, pp. 501 - 511, http://dx.doi.org/10.1007/s10549-021-06456-5
,2022, 'Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status', Drug Design, Development and Therapy, 16, pp. 2933 - 2948, http://dx.doi.org/10.2147/DDDT.S380925
,2022, '211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study', Annals of Oncology, 33, pp. S633 - S634, http://dx.doi.org/10.1016/j.annonc.2022.07.250
,2021, 'Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study', Annals of Oncology, 32, pp. 1571 - 1581, http://dx.doi.org/10.1016/j.annonc.2021.09.015
,2021, 'Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25422-9
,2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, http://dx.doi.org/10.1186/s13073-021-00885-z
,2021, 'Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models', Breast Cancer Research, 23, http://dx.doi.org/10.1186/s13058-021-01461-4
,2021, 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)', Nature Communications, 12, http://dx.doi.org/10.1038/s41467-021-25901-z
,2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x
,2021, 'MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer', Frontiers in Oncology, 11, http://dx.doi.org/10.3389/fonc.2021.777867
,2021, 'Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: A systematic review and meta-analysis of randomized trials', Cancers, 13, pp. 5527, http://dx.doi.org/10.3390/cancers13215527
,2021, 'Type 1 nuclear receptor activity in breast cancer: Translating preclinical insights to the clinic', Cancers, 13, pp. 4972, http://dx.doi.org/10.3390/cancers13194972
,2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722
,2021, 'A single-cell and spatially resolved atlas of human breast cancers', Nature Genetics, 53, pp. 1334 - 1347, http://dx.doi.org/10.1038/s41588-021-00911-1
,